Chemical inhibitors of C20orf77 function through various biochemical mechanisms to inhibit the protein's activity. Staurosporine, a well-known protein kinase inhibitor, disrupts the phosphorylation events that are critical for the activity of many proteins, including C20orf77. By inhibiting these kinases, Staurosporine can prevent the phosphorylation that C20orf77 might require for its function. Similarly, Wortmannin and LY294002, both phosphoinositide 3-kinases (PI3K) inhibitors, disrupt signaling pathways that C20orf77 relies upon. By inhibiting PI3K, these chemicals can prevent the activation of downstream targets that may be essential for the function of C20orf77. Rapamycin, by inhibiting the mammalian target of rapamycin (mTOR), can also disrupt downstream signaling pathways associated with C20orf77, potentially inhibiting its function. This is similar to the action of U0126 and PD98059, which selectively inhibit MEK1/2 and MEK respectively, thereby preventing the activation of the ERK pathway, a pathway that C20orf77 may depend on for its activity.
Furthermore, SB203580 targets p38 MAP Kinase, which is involved in response to stress and cytokines. Inhibition of p38 MAPK by SB203580 can interrupt signaling cascades that C20orf77 is part of, leading to its inhibition. SP600125, a JNK inhibitor, can halt signaling processes that are essential for C20orf77's activity. Triciribine aims at AKT inhibition, which prevents the phosphorylation and activation of proteins that are in the same pathway as C20orf77, thus leading to its functional inhibition. Dasatinib, a broad-spectrum tyrosine kinase inhibitor, can suppress the activity of kinases that regulate the activity of proteins such as C20orf77. Leflunomide inhibits dihydroorotate dehydrogenase, which can reduce the synthesis of proteins that are part of C20orf77's pathway, resulting in functional inhibition. Lastly, Bortezomib, as a proteasome inhibitor, causes the accumulation of misfolded proteins, disrupting cellular homeostasis and potentially inhibiting the function of C20orf77 through stress-induced pathways. Each chemical operates by disrupting specific pathways or cellular processes that are crucial for the proper functioning of C20orf77, thereby achieving inhibition.
関連項目
Items 1 to 10 of 12 total
展示:
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | ¥925.00 ¥1692.00 ¥4377.00 | 113 | |
Staurosporine 可抑制蛋白激酶,从而抑制 C20orf77 活性所必需的磷酸化事件。 | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | ¥745.00 ¥2471.00 ¥4705.00 | 97 | |
Wortmannin 是磷酸肌酸 3- 激酶的抑制剂,可能会破坏 C20orf77 发挥功能所依赖的信号通路。 | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | ¥1365.00 ¥4423.00 | 148 | |
另一种 PI3K 抑制剂 LY294002 也可能会破坏 C20orf77 发挥功能所必需的途径。 | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | ¥699.00 ¥1749.00 ¥3610.00 | 233 | |
雷帕霉素抑制 mTOR,这可能是对调控 C20orf77 功能的信号通路产生下游效应所必需的。 | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | ¥711.00 ¥2719.00 | 136 | |
U0126 是 MEK1/2 的选择性抑制剂,可能会阻断 ERK 通路,而 ERK 通路可能对 C20orf77 的活性至关重要。 | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | ¥440.00 ¥1015.00 | 212 | |
PD98059 可抑制 MEK,从而阻断 ERK 通路的激活,这是 C20orf77 发挥作用的必要步骤。 | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | ¥993.00 ¥3858.00 | 284 | |
SB203580 专门针对 p38 MAP 激酶,可能会抑制 C20orf77 参与的信号级联。 | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | ¥301.00 ¥1128.00 | 257 | |
SP600125 可抑制 JNK,从而阻止 C20orf77 活性所必需的信号转导过程。 | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | ¥1151.00 ¥1557.00 | 14 | |
三尖杉酯碱可抑制 AKT,从而阻止与 C20orf77 处于同一通路的蛋白质的磷酸化和激活,导致其受到抑制。 | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | ¥530.00 ¥1636.00 | 51 | |
达沙替尼是一种广谱酪氨酸激酶抑制剂,可能会抑制参与调控 C20orf77 的激酶的活性。 |